AZTherapies commences Ph III Alzheimer's trial; GE researching gene editing;

> AZTherapies is kicking off a Phase III study of its Alzheimer's candidate, a novel formulation of two drugs approved for other indications featuring targeted delivery specific to the disease. Release

> GE is shedding its financial business to focus on its industrial segments, as well as the life sciences. The company's Dharmacon unit has a keen interest in gene editing, known as CRISPR. "We can manipulate genes quite precisely now. The easy part is to switch proteins on and off; an even more interesting application of CRISPR-Cas9 is to change protein expression in order to create, for example, complex synthetic gene circuits," said Anja Smith, Dharmacon's director of research and development. More